IP Library › Patent Application 11583427
Patent Application
App. No. 11/583,427

Neurite regeneration

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/583,427
Abstract

The present invention relates to the use of RARβ2 and/or an agonist thereof in the preparation of a medicament to cause neurite development, neurite growth and/or neurite regeneration.

Claims (6)

1 . A pharmaceutical composition comprising a minimal lentiviral vector comprising a nucleic acid sequence encoding RARβ2 in operable linkage with a promoter, and a pharmaceutically acceptable carrier or diluent.

2 . The pharmaceutical composition of claim 1 , wherein said nucleic acid sequence encoding RARβ2 is codon optimized.

3 . The pharmaceutical composition of claim 1 , wherein said minimal lentiviral vector is an HIV, EIAV, or FIV lentiviral vector.

4 . The pharmaceutical composition of claim 1 , wherein said promoter is a constitutive promoter, an inducible promoter or a tissue-specific promoter.

5 . The pharmaceutical composition of claim 1 , wherein said lentiviral vector is pseudotyped with a heterologous envelope.

6 . The pharmaceutical composition of claim 5 , wherein said heterologous envelope is VSV-G or Rabies-G.